ANDA 88229, held by Actavis Mid Atlantic. Thioridazine Hydrochloride.
As of Nov 16, 2026, ANDA 88229 (Thioridazine Hydrochloride), held by Actavis Mid Atlantic, was first approved by FDA on Aug 23, 1983, with 11 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Aug 23, 1983 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Thioridazine Hydrochloride100MG/ML · concentrate;oral | Thioridazine Hydrochloride | Discontinued |
| Feb 23, 2017 | Supplement 25Labeling · Standard review | Approved | None posted |
| Nov 3, 2015 | Supplement 24Labeling | Approved | None posted |
| Jul 24, 2002 | Supplement 19Manufacturing | Approved | None posted |
| Nov 26, 2001 | Supplement 18Labeling | Approved | None posted |
| Nov 20, 2000 | Supplement 17Manufacturing | Approved | None posted |
| Oct 23, 2000 | Supplement 16Manufacturing | Approved | None posted |
| Dec 5, 1997 | Supplement 14Manufacturing | Approved | None posted |
| Sep 25, 1997 | Supplement 13Manufacturing | Approved | None posted |
| Sep 28, 1990 | Supplement 10Manufacturing | Approved | None posted |
| Oct 31, 1989 | Supplement 8Labeling | Approved | None posted |
| Sep 3, 1986 | Supplement 5Manufacturing | Approved | None posted |
| Aug 23, 1983 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters